TDAC · Translational Development Acquisition Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - |
| SG&A | $281.2K | - | $213.7K | $1.7K | $0 | - | - | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - |
| D&A | - | - | - | - | - | - | - | - |
| Operating Income | ($281.2K) | - | ($61.3K) | ($221.1K) | $0 | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | - | - | $0 | - | - | - |
| Net Income | $1.33M | - | ($61.3K) | ($1.7K) | $0 | - | - | - |
| EPS - Basic | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.6K | $29.8K | $47.1K | $35.3K | $206.6K | $438.2K | $2.0K | $2.2K |
| Accounts Receivable | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | $16.2K | $1.3K | - |
| Current Assets | $75.3K | $39.5K | $80.6K | $156.1K | $415.4K | $650.2K | $2.0K | - |
| Total Assets | $183.35M | $181.70M | $179.98M | $178.18M | $176.60M | $175.00M | $2.0K | - |
| Current Liabilities | $861.1K | $544.1K | $422.8K | $284.7K | $322.9K | $210.3K | $509.7K | - |
| Long-term Debt | - | - | - | - | - | - | - | - |
| Total Liabilities | $6.90M | $6.58M | $6.46M | $6.32M | $6.36M | $6.25M | $509.7K | - |
| Stockholders' Equity | ($6.82M) | ($6.54M) | ($6.38M) | ($509.3K) | ($5.94M) | ($5.60M) | ($507.7K) | ($22.1K) |
| Retained Earnings | ($6.82M) | ($6.54M) | ($6.38M) | ($6.17M) | ($5.95M) | ($5.60M) | ($532.7K) | - |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($305.2K) | - | - | - | ($231.6K) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $300.0K | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - |
| Effective tax rate | 0.0% | - | - | - | - | - | - | - |
| Return on assets | 0.7% | - | -0.0% | -0.0% | 0.0% | - | - | - |
| Return on equity | -19.5% | - | 1.0% | 0.3% | 0.0% | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||
| Current ratio | 0.09 | 0.07 | 0.19 | 0.55 | 1.29 | 3.09 | 0.00 | - |
| Quick ratio | 0.09 | 0.07 | 0.19 | 0.55 | 1.29 | 3.09 | 0.00 | - |
| Cash ratio | 0.03 | 0.05 | 0.11 | 0.12 | 0.64 | 2.08 | 0.00 | - |
| Leverage | ||||||||
| Debt / Equity | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - |
| Equity multiplier | -26.87 | -27.77 | -28.21 | -349.83 | -29.71 | -31.26 | -0.00 | - |
| Liabilities / Assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 252.19 | - |
| Efficiency | ||||||||
| Asset turnover | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - |
| Valuation | ||||||||
| P / E | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | - | - | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -14.8% | -16.9% | - | - | - | -1002.6% | -2196.3% | - |
Peer comparison
Same SIC group: Blank Checks
Comparing Translational Development Acquisition Corp. against the 5 most active filers in the same SIC group.